Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB et al (1997) Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 7(4):261–269. https://doi.org/10.1016/s0960-9822(06)00122-9

Article  CAS  PubMed  Google Scholar 

Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ et al (2014) AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 4(9):1046–1061. https://doi.org/10.1158/2159-8290.CD-14-0337

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cui JJ (2014) A new challenging and promising era of tyrosine kinase inhibitors. ACS Med Chem Lett 5(4):272–274. https://doi.org/10.1021/ml500091p

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goan YG, Liu PF, Chang HW, Chen HC, Chen WC, Kuo SM et al (2019) Kinome-wide screening with small interfering RNA identified polo-like kinase 1 as a key regulator of proliferation in oral cancer cells. Cancers. https://doi.org/10.3390/cancers11081117

Article  PubMed  PubMed Central  Google Scholar 

Grozio A, Mills KF, Yoshino J, Bruzzone S, Sociali G, Tokizane K et al (2019) Slc12a8 is a nicotinamide mononucleotide transporter. Nat Metab 1(1):47–57. https://doi.org/10.1038/s42255-018-0009-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hsu WH, Yang JC, Mok TS, Loong HH (2018) Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol 29(1):i3–i9. https://doi.org/10.1093/annonc/mdx702

Article  PubMed  Google Scholar 

Ito S, Fujino Y, Ogata S, Hirayama-Kurogi M, Ohtsuki S (2018) Involvement of an orphan transporter, SLC22A18, in cell growth and drug resistance of human breast cancer MCF7 cells. J Pharm Sci 107(12):3163–3170. https://doi.org/10.1016/j.xphs.2018.08.011

Article  CAS  PubMed  Google Scholar 

Kang E, Kim K, Jeon SY, Jung JG, Kim HK, Lee HB et al (2022) Targeting CLK4 inhibits the metastasis and progression of breast cancer by inactivating TGF-beta pathway. Cancer Gene Ther 29(8–9):1168–1180. https://doi.org/10.1038/s41417-021-00419-0

Article  CAS  PubMed  Google Scholar 

Kim SY (2018) Cancer energy metabolism: shutting power off cancer factory. Biomol Ther (seoul) 26(1):39–44. https://doi.org/10.4062/biomolther.2017.184

Article  CAS  PubMed  Google Scholar 

Kim JY, Bai Y, Jayne LA, Hector RD, Persaud AK, Ong SS et al (2020) A kinome-wide screen identifies a CDKL5-SOX9 regulatory axis in epithelial cell death and kidney injury. Nat Commun 11(1):1924. https://doi.org/10.1038/s41467-020-15638-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M et al (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352(8):786–792. https://doi.org/10.1056/NEJMoa044238

Article  CAS  PubMed  Google Scholar 

Lavoro A, Falzone L, Tomasello B, Conti GN, Libra M, Candido S (2023) In silico analysis of the solute carrier (SLC) family in cancer indicates a link among DNA methylation, metabolic adaptation, drug response, and immune reactivity. Front Pharmacol 14:1191262. https://doi.org/10.3389/fphar.2023.1191262

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li AR, Chitale D, Riely GJ, Pao W, Miller VA, Zakowski MF et al (2008) EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn 10(3):242–248. https://doi.org/10.2353/jmoldx.2008.070178

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li L, Xia J, Cui R, Kong B (2021a) Solute carrier family 12 member 8 impacts the biological behaviors of breast carcinoma cells by activating TLR/NLR signaling pathway. Cytotechnology 73(1):23–34. https://doi.org/10.1007/s10616-020-00439-y

Article  CAS  PubMed  Google Scholar 

Li SL, Li ZF, Cao QW, Wang WZ (2021b) SLC12A8 plays a key role in bladder cancer progression and EMT. Open Med (wars) 16(1):58–67. https://doi.org/10.1515/med-2021-0013

Article  CAS  PubMed  Google Scholar 

Liu Q, Yu S, Zhao W, Qin S, Chu Q, Wu K (2018) EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol Cancer 17(1):53. https://doi.org/10.1186/s12943-018-0793-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Melosky B, Kambartel K, Hantschel M, Bennetts M, Nickens DJ, Brinkmann J et al (2022) Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: a meta-analysis. Mol Diagn Ther 26(1):7–18. https://doi.org/10.1007/s40291-021-00563-1

Article  CAS  PubMed  Google Scholar 

Midha A, Dearden S, McCormack R (2015) EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res 5(9):2892–911. https://www.ncbi.nlm.nih.gov/pubmed/26609494

Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497–1500. https://doi.org/10.1126/science.1099314

Article  CAS  PubMed  Google Scholar 

Saito Y, Soga T (2021) Amino acid transporters as emerging therapeutic targets in cancer. Cancer Sci 112(8):2958–2965. https://doi.org/10.1111/cas.15006

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sapio L, Di Maiolo F, Illiano M, Esposito A, Chiosi E, Spina A et al (2014) Targeting protein kinase A in cancer therapy: an update. EXCLI J 13:843–55. https://www.ncbi.nlm.nih.gov/pubmed/26417307.

Tan FL, Ooi A, Huang D, Wong JC, Qian CN, Chao C et al (2010) p38delta/MAPK13 as a diagnostic marker for cholangiocarcinoma and its involvement in cell motility and invasion. Int J Cancer 126(10):2353–2361. https://doi.org/10.1002/ijc.24944

Article  CAS  PubMed  Google Scholar 

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z (2017) GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 45(W1):W98–W102. https://doi.org/10.1093/nar/gkx247

Article  CAS  PubMed  PubMed Central  Google Scholar 

Walter AO, Sjin RT, Haringsma HJ, Ohashi K, Sun J, Lee K et al (2013) Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov 3(12):1404–1415. https://doi.org/10.1158/2159-8290.CD-13-0314

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu SG, Shih JY (2018) Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer 17(1):38. https://doi.org/10.1186/s12943-018-0777-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang B, Ma YB, Chu SH (2018) Silencing SATB1 overcomes temozolomide resistance by downregulating MGMT expression and upregulating SLC22A18 expression in human glioblastoma cells. Cancer Gene Ther 25(11–12):309–316. https://doi.org/10.1038/s41417-018-0040-3

Article  CAS  PubMed  Google Scholar 

Zhang Q, Liu Y, Chen P, Shi X, Liu Y, Shi L et al (2021) Solute carrier family 12 member 8 (SLC12A8) is a potential biomarker and related to tumor immune cell infiltration in bladder cancer. Bioengineered 12(1):4946–4961. https://doi.org/10.1080/21655979.2021.1962485

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zheng H, Long G, Zheng Y, Yang X, Cai W, He S et al (2022) Glycolysis-related SLC2A1 is a potential pan-cancer biomarker for prognosis and immunotherapy. Cancers. https://doi.org/10.3390/cancers14215344

Article  PubMed  PubMed Central  Google Scholar